Urokinase plasminogen activator (uPA) is tightly correlated with increased epithelial-mesenchymal transition (EMT), which contributes to a high rate of recurrence of pancreatic cancer [14, 15]. This evidence concerns the gene PLAU and pancreatic neoplasm.